API
< Back to all clusters
[HEALTH] · United States · 2 sources

started · updated

FDA removes boxed warnings from three menopausal hormone therapy products

The U.S. Food and Drug Administration (FDA) has approved updated labeling for three additional menopausal hormone therapy (MHT) products, removing boxed warnings related to cardiovascular disease, breast cancer, and probable dementia. These products are estradiol transdermal patches from two different applicants.

This decision follows a February 2026 action involving six other MHT products. The FDA began engaging with pharmaceutical companies regarding these changes in November 2025, and 29 companies have since submitted proposed labeling changes. The agency stated that these actions support the executive order “Advancing Women’s Health to Improve Outcomes in All Phases of Life.”

While the FDA acknowledged challenges regarding the availability of hormone replacement therapy patches due to rising demand, the agency stated it is not aware of an imminent risk of a nationwide shortage. The FDA continues to engage with the six manufacturers of approved estradiol transdermal patches to address access issues.

Entities

Alicia Jackson · Evernow · Food and Drug Administration · U.S. Department of Health and Human Services